The new brand aims at deploying Univercells’ technologies by accelerating the commercialization of the scale-X™ bioreactor portfolio and the NevoLine™ platform.

Brussels, Belgium - 5 May 2020

Univercells Technologies, a global provider of next-generation bioprocess technologies, launches today.  Under this new brand, the company will focus on the commercialization of the product portfolio and will explore new technology developments to expand its position in the cell and gene therapy market.

According to Mathias Garny, General Manager of Univercells Technologies “With the scale-X™ bioreactor portfolio and the NevoLine™ biomanufacturing platform, designed and commercially validated by Univercells, the company experiences today a turning point. The commercialization of these cutting-edge technologies under a dedicated brand will boost the expansion of our market reach to support advances in cell and gene therapy manufacturing,”

Hundreds of cell and gene therapies are entering clinical trials but commercial progress remains stunted by manufacturing solutions inducing capacity and reproducibility constraints when facing process scale-up. Univercells Technologies will offer the scale-X bioreactor portfolio and the NevoLine platform to cell and gene therapy manufacturers seeking an effective and validated solution for scalable therapy manufacturing. The technology portfolio is equally suited to allow mass production of human and veterinary vaccines, delivering large quantities at an affordable cost.

“After years of innovative thinking we are proud to accelerate the commercialization of our intensified biomanufacturing technologies. They offer high-performing production capacities in a low-footprint while significantly reducing capital and operational costs. Univercells Technologies ambitions to support cell and gene therapy manufacturers in accelerating their developments and facilitating scalability from clinical phases to commercial manufacturing.” said José Castillo, Chief Technology Officer of Univercells Technologies.

The new company’s positioning is embodied by a dedicated brand and a logo that represents the strong Univercells heritage combined with a new technology focus. In addition to immediate access to the scale-X bioreactor portfolio and NevoLine biomanufacturing platform, the team will continue expanding the technology portfolio to accommodate evolving customer needs and pioneer the next evolution of biomanufacturing. For equipment inquiries, please contact customer@univercellstech.com.

Univercells Technologies Launch for the development and commercialization of intensified and automated biomanufacturing technologies

About Univercells

Univercells is an innovative bioprocessing provider focused on increasing the availability of affordable biologics. Capitalizing on unmatched bioprocessing and engineering expertise, the company offers leading-edge manufacturing solutions to alleviate the industry’s current shortfall in supply of cell and gene therapies, vaccines and biotherapeutics. Univercells is dedicated to delivering technologies, services and turnkey solutions to help industry experts unlock and expedite critically needed therapies.

A global company headquartered in Gosselies, Belgium, Univercells benefits from the support regional and national players as well as from the Bill & Melinda Gates Foundation (BMGF), Global Health Investment Fund (GHIF), European Investment Bank (EIB) and other international players in the health industry.

www.univercells.com

Univercells logo - biologics for all! Biotech Belgium

About Univercells Technologies

Univercells Technologies is a global provider of innovative biomanufacturing technologies to achieve cost-effective viral production from R&D to commercial scales. The company offers a comprehensive technology portfolio leveraging the strengths of process intensification and chaining as a direct answer to the growing demand of viral vectors and viral vaccines. Univercells Technologies is committed to helping customers increase performance with minimized footprint and costs today, while anticipating the needs of tomorrow.

Building upon years of expertise and capitalizing on technology vetted by world leaders, Univercells Technologies was incorporated in Belgium in 2020.

LinkedIn: Univercells Technologies

www.univercellstech.com

  • Univercells Technologies to focus on intensified, automated biomanufacturing technologies

    Download
  • Lancement d’Univercells Technologies pour la commercialisation de technologies de bioproduction révolutionnaires

    Download
  • Univercells Technologies: geïntensiveerde en geautomatiseerde bioprocestechnologie

    Download